BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 15897588)

  • 1. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP.
    Kobayashi H; Nagato T; Oikawa K; Sato K; Kimura S; Aoki N; Omiya R; Tateno M; Celis E
    Clin Cancer Res; 2005 May; 11(10):3869-78. PubMed ID: 15897588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP.
    Carlsson B; Tötterman TH; Essand M
    Prostate; 2004 Oct; 61(2):161-70. PubMed ID: 15305339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining MHC class II T helper epitopes for WT1 tumor antigen.
    Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
    Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
    Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E
    Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation.
    Kobayashi H; Omiya R; Sodey B; Yanai M; Oikawa K; Sato K; Kimura S; Senju S; Nishimura Y; Tateno M; Celis E
    Clin Cancer Res; 2003 Nov; 9(14):5386-93. PubMed ID: 14614024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avidity characterization of genetically engineered T-cells with novel and established approaches.
    Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
    BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.
    Oh S; Terabe M; Pendleton CD; Bhattacharyya A; Bera TK; Epel M; Reiter Y; Phillips J; Linehan WM; Kasten-Sportes C; Pastan I; Berzofsky JA
    Cancer Res; 2004 Apr; 64(7):2610-8. PubMed ID: 15059918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal adhesion kinase as an immunotherapeutic target.
    Kobayashi H; Azumi M; Kimura Y; Sato K; Aoki N; Kimura S; Honma M; Iizuka H; Tateno M; Celis E
    Cancer Immunol Immunother; 2009 Jun; 58(6):931-40. PubMed ID: 18941742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer.
    Azumi M; Kobayashi H; Aoki N; Sato K; Kimura S; Kakizaki H; Tateno M
    J Urol; 2010 May; 183(5):2036-44. PubMed ID: 20303532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
    Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
    Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma.
    Rodeberg DA; Erskine C; Celis E
    J Pediatr Surg; 2007 Aug; 42(8):1396-402. PubMed ID: 17706503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells.
    Hillerdal V; Nilsson B; Carlsson B; Eriksson F; Essand M
    Proc Natl Acad Sci U S A; 2012 Sep; 109(39):15877-81. PubMed ID: 23019373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes.
    Kobayashi H; Ngato T; Sato K; Aoki N; Kimura S; Tanaka Y; Aizawa H; Tateno M; Celis E
    Clin Cancer Res; 2006 Jun; 12(12):3814-22. PubMed ID: 16778109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
    Kobayashi H; Wood M; Song Y; Appella E; Celis E
    Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition of adult T-cell leukemia/lymphoma cells by CD4+ helper T lymphocytes specific for human T-cell leukemia virus type I envelope protein.
    Kobayashi H; Nagato T; Yanai M; Oikawa K; Sato K; Kimura S; Tateno M; Omiya R; Celis E
    Clin Cancer Res; 2004 Oct; 10(20):7053-62. PubMed ID: 15501985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen.
    Kobayashi H; Omiya R; Ruiz M; Huarte E; Sarobe P; Lasarte JJ; Herraiz M; Sangro B; Prieto J; Borras-Cuesta F; Celis E
    Clin Cancer Res; 2002 Oct; 8(10):3219-25. PubMed ID: 12374692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
    Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
    Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.